These risks and uncertainties include, among other things, the risks that efforts to develop VX-770 or VX-809 may not proceed due to technical, scientific, commercial, financial or other reasons, that clinical trials may not proceed as planned due to drug supply or patient enrollment issues, that additional clinical trials of VX-770 or VX-809 will not reflect the results obtained in the studies to